JUNIPER (JNP) ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigation of Juniper Pharmaceuticals, Inc.; Encourages Long-Term Investors to Contact the Firm

SAN DIEGO, Oct. 25, 2016 /PRNewswire/ -- Johnson & Weaver, LLP has commenced an investigation concerning whether Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) violated federal or state securities laws. Juniper focuses on developing therapeutics that addresses unmet medical needs in women's health.

On October 24, 2016, in a regulatory filing Juniper stated that its annual statements for 2013 to 2015 as well as its statements for the quarters ended March 31 and June 30, 2016, should no longer be relied upon. The Company will have to restate its financial statements due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA.

On the news Juniper stock was down 10% in early morning trading on October 25, 2016.

If you are a Juniper shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO

SOURCE Johnson & Weaver, LLP

Related Links

http://johnsonandweaver.com